Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 79.49% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 116.67K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 116.67K.
Overvalued
The company’s latest PE is -1.29, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 629.79K shares, decreasing 48.62% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 29.96K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.88.